-
Cagrilintide: 50/100mg
$529.00-$1,699.00
$600.00-$2,300.00 -
Thymosin Alpha-1: 50/250/500mg
$169.00-$1,190.00
$199.00-$1,690.00 -
Tirzepatide: 25/55/110 mg
$229.00-$1,499.00
$250.00-$2,000.00
Tirzepatide: 25/55/110 mg
$229.00-$1,499.00$250.00-$2,000.00
Research Only.
The capacity of Tirzepatide has been upgraded as follows and the prices remain unchanged:
- 2mg to 2.5mg/vial (25mg/ kit)
- 5mg to 5.5mg/vial (55mg/ kit)
- 10mg to 11mg/vial (110mg/ kit)
Description
Tirzepatide information
Name: Tirzepatide
CAS No.: 2023788-19-2
Molecular Formula: C225H348N48O68
Molecular Weight: 4813.527
Appearance: White Lyophilized powder
Packing: 1 kit 10vials;
- 2.5mg/vial (25mg/ kit)
- 5mg to 5.5mg/vial (55mg/ kit)
- 10mg to 11mg/vial (110mg/ kit)
Package: White Labelling vials. Labels can be customized.
Tirzepatide
Tirzepatide is a treatment of type 2 diabetes mellitus. It is an investigational dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, which means that it stimulates the release of insulin in response to glucose levels in the blood, thereby lowering blood sugar levels. Tirzepatide has shown promising results in clinical trials for its efficacy and safety in controlling blood glucose levels, reducing body weight, and improving cardiovascular outcomes.
History and Development
The development of Tirzepatide began in 2015, and it is the result of years of research into the role of GIP and GLP-1 in glucose regulation and metabolism. The drug is a fusion protein consisting of the GLP-1 receptor agonist dulaglutide and the GIP receptor agonist tirzepatide.
The first phase II clinical trial was conducted in 2017, and the results showed that Tirzepatide was effective in reducing blood sugar levels and body weight in patients with type 2 diabetes. The phase III clinical trials, SURPASS-1 and SURPASS-2, were completed in 2020, and the results were published in the New England Journal of Medicine. These trials showed that Tirzepatide was superior to other standard-of-care treatments in controlling blood sugar levels and reducing body weight in patients with type 2 diabetes.
Mechanism of Action
Tirzepatide is a dual GIP and GLP-1 receptor agonist, which means that it stimulates the release of insulin in response to glucose levels in the blood. GIP and GLP-1 are hormones produced in the gut that play a crucial role in glucose regulation and metabolism. GIP stimulates the release of insulin from the pancreas in response to glucose levels in the blood, while GLP-1 stimulates the release of insulin and inhibits the release of glucagon, which is a hormone that raises blood sugar levels. Tirzepatide binds to both GIP and GLP-1 receptors, thereby enhancing the glucose-lowering effects of both hormones.
Clinical Trials
Tirzepatide has undergone several clinical trials to evaluate its safety, efficacy, and tolerability in the treatment of type 2 diabetes.
Phase 1 and 2 Trials
The initial phase 1 and 2 trials demonstrated promising results in terms of glycemic control and weight loss. Tirzepatide was generally well-tolerated, with the most common side effects being gastrointestinal in nature, such as nausea, vomiting, and diarrhea.
Phase 3 Trials
The phase 3 clinical trial program for tirzepatide, known as the SURPASS trials, included multiple randomized, controlled studies. These trials compared tirzepatide to various other diabetes medications, including insulin glargine, dulaglutide, and semaglutide. The results from the SURPASS trials demonstrated that tirzepatide provided superior glycemic control and weight loss compared to the control groups.
Effectiveness
Several phase 3 clinical trials have evaluated the effectiveness of tirzepatide in adults with type 2 diabetes. Key findings include:
- A1c reduction. Tirzepatide has been shown to lower A1c (a measure of long-term blood sugar control) by 1.5% to 2% within 26 weeks of treatment, depending on the dose. This level of A1c reduction is comparable or superior to many other type 2 diabetes medications.
- Fasting blood sugar reduction. Fasting blood sugar levels dropped by 40 to 70 mg/dL within 26 weeks of treatment with tirzepatide in clinical trials.
- Weight loss. Study participants taking tirzepatide lost an average of 8-12% of their body weight. This is among the greatest weight loss of any type 2 diabetes drug.
- Sustained effects. Available data indicate that the effects of tirzepatide on blood sugar and weight are maintained for at least 2 years of therapy.
The clinical trials also found that tirzepatide was effective when added to other diabetes medications like metformin, SGLT2 inhibitors and insulin. Many patients were able to either reduce or stop their existing diabetes medications when taking tirzepatide.
Overall, the effectiveness data suggest tirzepatide may become a cornerstone treatment for many people with type 2 diabetes.
Side effects and safety
Common side effects reported with tirzepatide in clinical trials have included:
- Nausea
- Diarrhea
- Vomiting
- Abdominal pain
- Decreased appetite
These side effects often lessen or go away over time as the body adjusts to the medication. Up to 10% of patients discontinued treatment with tirzepatide due to side effects in the initial phase 3 trials.
Other potential safety concerns include:
- Hypoglycemia. Since tirzepatide stimulates insulin secretion, there is a risk of low blood sugar, especially in combination with other diabetes medications that can also lower blood sugar. However, the risk appears to be low when used as monotherapy.
- Injection site reactions. Like other injectable drugs, redness, itching and swelling at the injection site can occur but are typically mild.
- Pancreatitis. There have been rare cases of pancreatitis reported in patients taking tirzepatide or other GLP-1 agonists. However, the overall risk appears to be low.
- Heart risks. Based on the mechanisms of action of GLP-1 agonists, there are theoretical concerns that they may increase the risk of heart rhythm problems, heart failure and other cardiovascular issues. So far, data from clinical trials suggest there is no increased risk but longer-term safety monitoring is needed.
- Gallbladder disease. Like other GLP-1 agonists, tirzepatide may increase the risk of gallstones and cholecystitis. Periodic monitoring of the gallbladder is recommended.
Still, tirzepatide appears to have a safety profile similar to other GLP-1 receptor agonists and has not revealed any entirely new safety concerns to date. However, it remains a relatively new drug so longer-term safety data are still needed.
Precautions
Tirzepatide should not be used in patients with a history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. It should also not be used in patients with a history of severe gastrointestinal disease, such as gastroparesis or inflammatory bowel disease.
Cost and insurance
The list price for tirzepatide is currently set at:
- 5 mg dose: $674.50 for a 4-week supply
- 10 mg dose: $674.50 for a 4-week supply
- 15 mg dose: $674.50 for a 4-week supply
At these prices, the annual cost of treatment would range from $8,794 to $26,382 depending on the dose required. However, most patients’ out-of-pocket costs will be lower due to insurance coverage and financial assistance programs.
Insurance coverage for tirzepatide will vary by plan. Typically, newly launched drugs like tirzepatide are subject to some restrictions in the first year or two, such as prior authorization requirements or only being covered in certain steps of therapy. However, coverage is likely to become more generous over time if the drug proves effective and safe.
The manufacturer also offers a patient assistance program for those who qualify, which may help reduce out-of-pocket costs for eligible patients without insurance or with high deductibles.
Who should use tirzepatide?
Tirzepatide may be appropriate for patients with type 2 diabetes who:
- Are unable to achieve adequate blood glucose control with metformin, lifestyle changes or other oral diabetes medications
- Would benefit from weight loss to improve their diabetes and overall health
- Need a once-weekly injectable medication to simplify their treatment regimen
- Are motivated to adhere to regular injectable therapy
- Can tolerate potential side effects in exchange for better blood sugar and weight control
Tirzepatide is likely to be most effective for patients with a body mass index over 25 kg/m2, as its weight loss effects increase with higher weight. Patients who have difficulty tolerating GLP-1 receptor agonists may also have issues with tirzepatide.
Physicians typically consider adding tirzepatide to a patient’s treatment regimen after lifestyle modifications and metformin alone are no longer sufficient. It can then be used alone or in combination with other diabetes medications.
In summary, tirzepatide appears to offer a promising new option for many patients with type 2 diabetes, especially those seeking both improved blood sugar control and weight loss benefits. However, each patient’s specific situation, risks and priorities should be evaluated by their healthcare provider.
Differences between tirzepatide and semaglutide
- Mechanism of action – Tirzepatide is a dual GLP-1 and GIP receptor agonist, while semaglutide only activates the GLP-1 receptor. This gives tirzepatide additional effects through GIP receptor activation, including potentially greater insulin secretion and beta cell protection.
- Effectiveness – Tirzepatide has shown slightly greater improvements in A1c and significantly higher weight loss compared to semaglutide in clinical trials. This is likely due to tirzepatide’s additional GIP receptor activation.
- Side effects – The side effect profiles of the two drugs appear similar, with both commonly causing nausea, diarrhea and vomiting. However, tirzepatide may cause more mild to moderate gastrointestinal side effects in the first few months of treatment due to its dual receptor activation.
- Dosing – Semaglutide is injected once weekly at fixed doses of 0.5 mg, 1 mg or 2 mg. Tirzepatide is started at 5 mg or 10 mg and then increased in increments of 5 mg or 10 mg per week up to 15 mg based on patient response. This individualized dosing may allow for improved outcomes.
In summary, while both drugs work by activating the GLP-1 receptor, tirzepatide’s additional effects through GIP receptor activation appear to offer slightly greater improvements in blood sugar control and significantly higher weight loss. However, tirzepatide also has a longer-term safety profile that has yet to be fully established.
Frequently Asked Questions
Q: What is Tirzepatide?
A: Tirzepatide is the treatment of type 2 diabetes mellitus. It is an investigational dual GIP and GLP-1 receptor agonist that stimulates the release of insulin in response to glucose levels in the blood, thereby lowering blood sugar levels.
Q: How does Tirzepatide work?
A: Tirzepatide is a dual GIP and GLP-1 receptor agonist that binds to both GIP and GLP-1 receptors, thereby enhancing the glucose-lowering effects of both hormones. It stimulates the release of insulin in response to glucose levels in the blood, thereby lowering blood sugar levels.
Q: What are the clinical trials that have been conducted on Tirzepatide?
A: Tirzepatide has undergone several clinical trials to evaluate its safety and efficacy in patients with type 2 diabetes. The phase II clinical trial, SURPASS-2, and the phase III clinical trials, SURPASS-1 and SURPASS-2, have shown promising results in controlling blood glucose levels, reducing body weight, and improving cardiovascular outcomes.
Q: What are the side effects of Tirzepatide?
A: The most common side effects of Tirzepatide are gastrointestinal symptoms such as nausea, vomiting, and diarrhea. Other side effects include headache, fatigue, and injection site reactions such as redness, swelling, and itching.
Q: What is the recommended dosage of Tirzepatide?
A: The recommended starting dose of Tirzepatide is 5 mg once a week. The dose can be increased to 10 mg or 15 mg once a week based on the patient’s response and tolerability.
Q: What precautions should be taken while using Tirzepatide?
A: Tirzepatide should not be used in patients with a history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. It should also not be used in patients with a history of severe gastrointestinal disease, such as gastroparesis or inflammatory bowel disease.
Q: Can tirzepatide be used in combination with insulin?
A: Yes, tirzepatide has been studied in combination with basal, premixed and prandial insulin in type 2 diabetes patients. In clinical trials, many patients achieved better blood sugar control on a lower insulin dose when tirzepatide was added. Combining the two medications may require close monitoring to prevent low blood sugar reactions.
Q: Does tirzepatide affect mood?
A: Tirzepatide may cause low blood sugar (hypoglycemia). Symptoms and signs of low blood sugar may include dizziness or lightheadedness, blurred vision, anxiety, irritability or mood changes, sweating, slurred speech, hunger, confusion or drowsiness, shakiness, weakness, headache, fast heart rate and feeling jittery.
Q: Can you drink on tirzepatide?
A: Alcohol may affect blood glucose levels in patients with diabetes. Both hypoglycemia (low blood sugar) and hyperglycemia (high blood sugar) may occur, depending on how much and how often you drink.
Q: When is the best time to inject tirzepatide?
A: Tirzepatide comes as a solution (liquid) in a pre-filled pen to be injected subcutaneously (under the skin). It is usually given once a week with or without meals at any time of day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand.
Q: Can I get tirzepatide if I don’t have diabetes?
A: Tirzepatide is a medication approved for the treatment of type 2 diabetes, but it has shown incredible results for weight loss, even for people who do not have diabetes.
Q: Can you buy tirzepatide for weight loss?
A: There is proof that its active ingredient is safe and effective in treating overweight or obesity.
Q: How do I Store Tirzepatide?
A: Keep out of the reach of children.
Do not keep outdated medicine or medicine no longer needed.
Ask your healthcare professional how you should dispose of any medicine you do not use.
Store in the refrigerator. Do not freeze.
Store your medicine pen in its original carton in the refrigerator. Do not freeze. You may store the pen at room temperature for up to 21 days.
Throw away used needles in a hard, closed container that the needles cannot poke through. Keep this container away from children and pets.
Q: How quickly does tirzepatide start working?
A: Most of tirzepatide’s blood sugar lowering and weight loss effects become apparent within the first 3 months of treatment for most patients. Some may see benefits sooner. The full effects gradually increase over time as the dose is increased.
Conclusion
Tirzepatide is a treatment of type 2 diabetes mellitus. It is an investigational dual GIP and GLP-1 receptor agonist that stimulates the release of insulin in response to glucose levels in the blood, thereby lowering blood sugar levels. Tirzepatide has shown promising results in clinical trials for its efficacy and safety in controlling blood glucose levels, reducing body weight, and improving cardiovascular outcomes. However, further studies are needed to confirm its long-term safety and efficacy.
Research use only. Not for human or animal consumption!
Additional information
| Weight | 200 g |
|---|---|
| Dimensions | 10 × 10 × 5 cm |
| Size | 10mg*10vials (100mg), 1Gram (raw powder 1000mg), 2mg*10vials (20mg), 5mg*10vials (50mg) |
Reviews(8)
You must be logged in to post a review.
Emma Garcia
(verified owner)I’ve noticed that my body responds more effectively to insulin since starting tirzepatide. This has been a relief as it means better overall diabetes management.
Isabella
(verified owner)Very good prices and top-notch product that delivers exactly as promised.
Oliver Wilson
(verified owner)Incredible value for the quality, I’m thoroughly impressed
Molloy
(verified owner)Me again:) My confidence has skyrocketed since I began seeing positive changes in my weight and overall health. Their Tirzepatide’s effects have had a positive impact on my self-esteem. Love you always supo team, you need a raise.
Lucas Taylor
(verified owner)Within just a few weeks of starting tirzepatide, I noticed a significant drop in my weight. It’s incredible how this medication’s effects are so visible.
Mia
(verified owner)Five stars aren’t enough for how satisfied I am with this purchase.
Liam Johnson
(verified owner)Initially, I was under the impression that the price was for a single 5mg vial. However, upon discussing this with the service team, they clarified that it’s actually 5mg * 10 vials, totaling 50mg. This turned out to be much more affordable compared to what I’ve ordered from other suppliers. I decided to give it a shot and used it for 4 weeks. The results have been truly amazing; it’s been incredibly effective. I can’t express my gratitude enough to them for offering such a great deal!
Ethan
(verified owner)Taking it has become a seamless part of my daily routine. Its ease of use has made managing my health simpler. TK.